Belantamab mafodotin combined with pomalidomide and dexamethasone in RRMM: HRQoL in DREAMM-8

12 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the health-related quality of life (HRQoL) results of the Phase III DREAMM-8 study (NCT04484623) evaluating belantamab mafodotin in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Dr Richardson highlights that the HRQoL of patients was substantially preserved and/or improved in the experimental arm. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo